Fate Therapeutics (FATE) Depreciation & Amortization (CF) (2012 - 2026)

Fate Therapeutics has reported Depreciation & Amortization (CF) for 15 years, with the latest figure at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 12.45% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $12.5 million (down 28.55% YoY), and the FY2025 full-year result was $12.9 million, down 31.96% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $2.9 million, down from $3.1 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $4.9 million in Q4 2023, with the low at $2.8 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $3.9 million across 5 years, with a median of $4.2 million in 2023.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 187.9% — and 2025, when it sank 36.36%.
• Fate Therapeutics' Depreciation & Amortization (CF) stood at $4.9 million in 2022, then climbed by 0.02% to $4.9 million in 2023, then declined by 1.47% to $4.8 million in 2024, then tumbled by 36.36% to $3.1 million in 2025, then dropped by 4.73% to $2.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.9 million (Q1 2026), $3.1 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.